Xiaoxiang Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiaoxiang Chen has a total of 227 co-authors. Here are the top co-authors by number of shared publications:
Yixuan Li
Department of Rheumatology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
10 shared publications- Liangjing Lu
Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
8 shared publications Ruru Guo
Department of Rheumatology, Renji Hospital Shanghai Jiao Tong University School of Medicine Shanghai China
7 shared publicationsShan Cao
Department of Allergy School of Medicine Renji Hospital Shanghai Jiao Tong University Shanghai China
7 shared publicationsXinyu Meng
Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University , Shanghai
7 shared publicationsYuyang Jin
Department of Rheumatology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
7 shared publications
Latest Publications
- Open Access
- 26 August 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1927065
Severe thrombocytopenia is associated with arterial thrombotic manifestations in antiphospholipid syndrome: a two-center cohort study
Objective: Thrombocytopenia in APS is often regarded primarily as a bleeding-related manifestation, but the relationship between platelet-count severity and thrombotic manifestations remains uncertain. We evaluated the association between severe thrombocytopenia and arterial thrombotic manifestations in patients with antiphospholipid syndrome (APS). Methods: In a two-center baseline cohort of 313 patients with APS, baseline platelet count (PLT) was categorized as PLT 9 /L, PLT 50–9 /L, or PLT ≥100×10 9 /L. Associations with prevalent baseline thrombotic manifestations were assessed using multivariable logistic regression in 300 patients with primary APS or systemic lupus erythematosus-associated APS. In the Renji follow-up cohort (n=254), 48-month thrombotic events were evaluated using Kaplan–Meier curves and Cox models. Results: PLT 9 /L was associated with a higher frequency of arterial thrombosis (66.7%), particularly cerebral infarction (62.7%), whereas venous thrombosis was most frequent in the PLT 50–9 /L group (68.4%). After multivariable adjustment, PLT 9 /L remained associated with a higher prevalence of arterial thrombosis (aOR 2.16, 95% CI 1.07–4.35, P = 0.032) and cerebral infarction (aOR 2.37, 95% CI 1.18–4.73, P = 0.015). During 48-month follow-up, PLT 9 /L was associated with increased risks of any thrombotic event (HR 3.28, 95% CI 1.54–6.97, P = 0.002), arterial thrombotic event (HR 3.95, 95% CI 1.39–11.21, P = 0.010), and cerebral infarction (HR 4.11, 95% CI 1.44–11.73, P = 0.008), but not venous-related events. Conclusion: Severe thrombocytopenia was associated with arterial thrombotic manifestations in APS, particularly cerebral infarction. PLT 9 /L may provide additional clinical risk information but may also reflect cumulative disease burden and overall APS severity.
- 26 August 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1927065
Open AccessSevere thrombocytopenia is associated with arterial thrombotic manifestations in antiphospholipid syndrome: a two-center cohort study
Objective: Thrombocytopenia in APS is often regarded primarily as a bleeding-related manifestation, but the relationship between platelet-count severity and thrombotic manifestations remains uncertain. We evaluated the association between severe thrombocytopenia and arterial thrombotic manifestations in patients with antiphospholipid syndrome (APS). Methods: In a two-center baseline cohort of 313 patients with APS, baseline platelet count (PLT) was categorized as PLT 9 /L, PLT 50–9 /L, or PLT ≥100×10 9 /L. Associations with prevalent baseline thrombotic manifestations were assessed using multivariable logistic regression in 300 patients with primary APS or systemic lupus erythematosus-associated APS. In the Renji follow-up cohort (n=254), 48-month thrombotic events were evaluated using Kaplan–Meier curves and Cox models. Results: PLT 9 /L was associated with a higher frequency of arterial thrombosis (66.7%), particularly cerebral infarction (62.7%), whereas venous thrombosis was most frequent in the PLT 50–9 /L group (68.4%). After multivariable adjustment, PLT 9 /L remained associated with a higher prevalence of arterial thrombosis (aOR 2.16, 95% CI 1.07–4.35, P = 0.032) and cerebral infarction (aOR 2.37, 95% CI 1.18–4.73, P = 0.015). During 48-month follow-up, PLT 9 /L was associated with increased risks of any thrombotic event (HR 3.28, 95% CI 1.54–6.97, P = 0.002), arterial thrombotic event (HR 3.95, 95% CI 1.39–11.21, P = 0.010), and cerebral infarction (HR 4.11, 95% CI 1.44–11.73, P = 0.008), but not venous-related events. Conclusion: Severe thrombocytopenia was associated with arterial thrombotic manifestations in APS, particularly cerebral infarction. PLT 9 /L may provide additional clinical risk information but may also reflect cumulative disease burden and overall APS severity.
- Open Access
- 22 June 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (12) , 1944
Association Between Systemic Inflammatory Response Biomarkers and Disease Activity in Systemic Lupus Erythematosus: A Multi-Center Retrospective Study
Objective: To evaluate the association of routine complete blood count (CBC)-derived inflammatory biomarkers, including neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), and systemic inflammation response index (SIRI), with disease activity and exploratory neuropsychiatric risk stratification in patients with systemic lupus erythematosus (SLE). Methods: In this multi-center retrospective study, 579 SLE patients and 282 healthy controls (HCs) were recruited from five clinical centers between 2018 and 2025. NLR, MLR, PLR, and SIRI were calculated from routine CBC parameters. Disease activity was assessed using the SLE Disease Activity Index 2000 (SLEDAI-2K), with high activity defined as SLEDAI-2K ≥ 10. The comparison between SLE patients and HCs was performed as an exploratory descriptive analysis to characterize systemic inflammatory profiles, whereas the primary analyses focused on associations with disease activity and NPSLE-related risk stratification. Results: SLE patients exhibited significantly higher levels of SIRI, NLR, PLR, and MLR compared to HCs (all p < 0.001). In this exploratory comparison, MLR showed the largest area under the curve for distinguishing SLE patients from HCs (AUC: 0.849, Cut-off: 0.263). In regression analyses, MLR, NLR, PLR, and SIRI were positively associated with SLEDAI-2K score. In multivariable linear regression analysis, MLR was associated with a higher SLEDAI-2K score (B = 4.600, 95% CI: 2.039–7.160, p < 0.001). In patients with available neuropsychiatric data, MLR, NLR, and SIRI were higher in patients with NPSLE than in those with non-NPSLE, whereas PLR showed no significant difference. SIRI showed modest exploratory discriminatory ability for NPSLE and may provide auxiliary information for NPSLE risk stratification (AUC: 0.710, p < 0.001, Cut-off: 1.438). Conclusions: Routine CBC-derived inflammatory biomarkers, particularly MLR, NLR, and SIRI, are associated with SLE disease activity and may serve as accessible, low-cost adjunctive tools for rapid clinical assessment. SIRI may provide additional auxiliary information for identifying patients at higher risk of neuropsychiatric involvement. However, these biomarkers should be interpreted as complementary screening or risk-stratification tools rather than substitutes for established disease activity indices or organ-specific evaluations. Further prospective studies are warranted to validate their clinical utility.
- 22 June 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (12) , 1944
Open AccessAssociation Between Systemic Inflammatory Response Biomarkers and Disease Activity in Systemic Lupus Erythematosus: A Multi-Center Retrospective Study
Objective: To evaluate the association of routine complete blood count (CBC)-derived inflammatory biomarkers, including neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), and systemic inflammation response index (SIRI), with disease activity and exploratory neuropsychiatric risk stratification in patients with systemic lupus erythematosus (SLE). Methods: In this multi-center retrospective study, 579 SLE patients and 282 healthy controls (HCs) were recruited from five clinical centers between 2018 and 2025. NLR, MLR, PLR, and SIRI were calculated from routine CBC parameters. Disease activity was assessed using the SLE Disease Activity Index 2000 (SLEDAI-2K), with high activity defined as SLEDAI-2K ≥ 10. The comparison between SLE patients and HCs was performed as an exploratory descriptive analysis to characterize systemic inflammatory profiles, whereas the primary analyses focused on associations with disease activity and NPSLE-related risk stratification. Results: SLE patients exhibited significantly higher levels of SIRI, NLR, PLR, and MLR compared to HCs (all p < 0.001). In this exploratory comparison, MLR showed the largest area under the curve for distinguishing SLE patients from HCs (AUC: 0.849, Cut-off: 0.263). In regression analyses, MLR, NLR, PLR, and SIRI were positively associated with SLEDAI-2K score. In multivariable linear regression analysis, MLR was associated with a higher SLEDAI-2K score (B = 4.600, 95% CI: 2.039–7.160, p < 0.001). In patients with available neuropsychiatric data, MLR, NLR, and SIRI were higher in patients with NPSLE than in those with non-NPSLE, whereas PLR showed no significant difference. SIRI showed modest exploratory discriminatory ability for NPSLE and may provide auxiliary information for NPSLE risk stratification (AUC: 0.710, p < 0.001, Cut-off: 1.438). Conclusions: Routine CBC-derived inflammatory biomarkers, particularly MLR, NLR, and SIRI, are associated with SLE disease activity and may serve as accessible, low-cost adjunctive tools for rapid clinical assessment. SIRI may provide additional auxiliary information for identifying patients at higher risk of neuropsychiatric involvement. However, these biomarkers should be interpreted as complementary screening or risk-stratification tools rather than substitutes for established disease activity indices or organ-specific evaluations. Further prospective studies are warranted to validate their clinical utility.
- Open Access
- 7 May 2026
- Published by Wiley in European Journal of Immunology
- Vol. 56 (5) , e70194
Mapping of Neutrophils in Cancers: Insights From Spatial Omics Technologies
Tumor neutrophils exhibit marked phenotypic plasticity and can play dual roles in tumor biology, encompassing both tumor‐promoting and tumor‐suppressive activities. Single‐cell RNA sequencing (scRNA‐seq) enables transcriptomic profiling of tumor neutrophils at single‐cell resolution, whereas spatial transcriptomics (ST) addresses key limitations of scRNA‐seq by preserving the spatial context of cells within intact tissue, thereby minimizing cell loss and maintaining native tissue architecture. As ST technology continues to advance, it offers increasingly comprehensive insights into the regulatory mechanisms of tumor neutrophils within the tumor microenvironment (TME). In this review, we first summarize recent technological advancements in ST. We then discuss neutrophil detection across various cancer types, highlighting key differences and challenges in neutrophil research across studies and malignancies. Furthermore, we outline recommendations for sequencing strategies and sample processing to optimize the study of tumor neutrophils. Finally, we highlight that integrating ST with multi‐omics approaches offers a promising avenue to advance our understanding of tumor neutrophil biology and to identify more precise biomarkers for targeted therapies.
- 7 May 2026
- Published by Wiley in European Journal of Immunology
- Vol. 56 (5) , e70194
Open AccessMapping of Neutrophils in Cancers: Insights From Spatial Omics Technologies
Tumor neutrophils exhibit marked phenotypic plasticity and can play dual roles in tumor biology, encompassing both tumor‐promoting and tumor‐suppressive activities. Single‐cell RNA sequencing (scRNA‐seq) enables transcriptomic profiling of tumor neutrophils at single‐cell resolution, whereas spatial transcriptomics (ST) addresses key limitations of scRNA‐seq by preserving the spatial context of cells within intact tissue, thereby minimizing cell loss and maintaining native tissue architecture. As ST technology continues to advance, it offers increasingly comprehensive insights into the regulatory mechanisms of tumor neutrophils within the tumor microenvironment (TME). In this review, we first summarize recent technological advancements in ST. We then discuss neutrophil detection across various cancer types, highlighting key differences and challenges in neutrophil research across studies and malignancies. Furthermore, we outline recommendations for sequencing strategies and sample processing to optimize the study of tumor neutrophils. Finally, we highlight that integrating ST with multi‐omics approaches offers a promising avenue to advance our understanding of tumor neutrophil biology and to identify more precise biomarkers for targeted therapies.
- 28 April 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (5)
Autoantibody reactome analysis reveals novel biomarkers for idiopathic retroperitoneal fibrosis
Objective: Idiopathic retroperitoneal fibrosis (iRPF) is a rare disease frequently misdiagnosed due to the lack of reliable biomarkers. This study aimed to identify novel autoantibodies to improve the diagnosis and differential diagnosis of iRPF. Methods: A total of 33 patients with iRPF, 100 healthy controls, 11 with retroperitoneal sarcoma (RPS) and 74 with other autoimmune diseases were recruited from Renji Hospital from January 2018 to April 2025. Autoantibodies were screened using the Sengenics Immunome Protein Array. Their expression and particularly their IgG4 subclass were then validated by enzyme-linked immunosorbent assay (ELISA) and dot blot assays. Pearson correlation and receiver operating characteristic (ROC) curve analyses were performed with clinical parameters to evaluate their diagnostic performance. Results: Plasma levels of autoantibodies targeting recombination signal binding protein for immunoglobulin kappa J region (RBPJ), tropomyosin alpha-1 (TPM1), nuclear nucleic acid-binding protein (C1D), nucleophosmin 1 (NPM1) and interleukin-1α (IL-1A) were significantly elevated in iRPF patients compared with healthy controls. Among these, anti-TPM1 antibody levels positively correlated with hydronephrosis severity (P < 0.05) and serum creatinine concentrations (P < 0.01), and declined after treatment, suggesting their potential as biomarkers of renal injury and disease activity. Anti-RBPJ antibodies increased after treatment (P < 0.01) and showed a negative correlation with IL-6 (P < 0.05), suggesting the potential for protective antibodies. Anti-C1D antibodies distinguished iRPF from RPS (P < 0.01, AUC = 0.718), and their IgG4 subclass was associated with a Th1/Th2 imbalance and renal impairment. Anti-NPM1 IgG4/IgG ratio was positively correlated with renal injury markers and Th2-type cytokines. Conclusion: This study identified five autoantibodies with diagnostic potential for iRPF, providing a novel basis for early detection, disease monitoring and further mechanistic investigations.
- 28 April 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (5)
Autoantibody reactome analysis reveals novel biomarkers for idiopathic retroperitoneal fibrosis
Objective: Idiopathic retroperitoneal fibrosis (iRPF) is a rare disease frequently misdiagnosed due to the lack of reliable biomarkers. This study aimed to identify novel autoantibodies to improve the diagnosis and differential diagnosis of iRPF. Methods: A total of 33 patients with iRPF, 100 healthy controls, 11 with retroperitoneal sarcoma (RPS) and 74 with other autoimmune diseases were recruited from Renji Hospital from January 2018 to April 2025. Autoantibodies were screened using the Sengenics Immunome Protein Array. Their expression and particularly their IgG4 subclass were then validated by enzyme-linked immunosorbent assay (ELISA) and dot blot assays. Pearson correlation and receiver operating characteristic (ROC) curve analyses were performed with clinical parameters to evaluate their diagnostic performance. Results: Plasma levels of autoantibodies targeting recombination signal binding protein for immunoglobulin kappa J region (RBPJ), tropomyosin alpha-1 (TPM1), nuclear nucleic acid-binding protein (C1D), nucleophosmin 1 (NPM1) and interleukin-1α (IL-1A) were significantly elevated in iRPF patients compared with healthy controls. Among these, anti-TPM1 antibody levels positively correlated with hydronephrosis severity (P < 0.05) and serum creatinine concentrations (P < 0.01), and declined after treatment, suggesting their potential as biomarkers of renal injury and disease activity. Anti-RBPJ antibodies increased after treatment (P < 0.01) and showed a negative correlation with IL-6 (P < 0.05), suggesting the potential for protective antibodies. Anti-C1D antibodies distinguished iRPF from RPS (P < 0.01, AUC = 0.718), and their IgG4 subclass was associated with a Th1/Th2 imbalance and renal impairment. Anti-NPM1 IgG4/IgG ratio was positively correlated with renal injury markers and Th2-type cytokines. Conclusion: This study identified five autoantibodies with diagnostic potential for iRPF, providing a novel basis for early detection, disease monitoring and further mechanistic investigations.
- Open Access
- 24 February 2026
- Published by Springer Nature in BMC Pediatrics
- Vol. 26 (1)
Rare pediatric Saccharomyces cerevisiae fungemia with neutralizing anti-IL-23 autoantibodies: a case report
Anti-IL-23 autoantibodies are associated with severe, persistent opportunistic infections. We described the first pediatric case of Saccharomyces cerevisia
- 24 February 2026
- Published by Springer Nature in BMC Pediatrics
- Vol. 26 (1)
Open AccessRare pediatric Saccharomyces cerevisiae fungemia with neutralizing anti-IL-23 autoantibodies: a case report
Anti-IL-23 autoantibodies are associated with severe, persistent opportunistic infections. We described the first pediatric case of Saccharomyces cerevisia
- Open Access
- 1 December 2025
- Published by Tsinghua University Press in Nano Biomedicine and Engineering
- Vol. 17 (4) , 455-480
Metal Isotope-Tagged Nanomaterials for Mass Cytometry and Imaging: Advances and Biomedical Applications
Mass cytometry (cytometry by time-of-flight (CyTOF)) and imaging mass cytometry (IMC) are transformative technologies that combine flow cytometry principles with time-of-flight mass spectrometry (TOF-MS). By employing metal isotope-tagged antibodies instead of fluorophores, these techniques overcome spectral overlap limitations and enable high-dimensional, compensation-free analysis of complex biological systems at single-cell resolution. The performance of CyTOF and IMC critically depends on advanced nanomaterials labeled with stable metal isotopes, which are essential for improving sensitivity and multiplexing capacity. This review systematically discusses the design principles, synthesis methods, and functionalization strategies of mass-tagged nanomaterials tailored for CyTOF (e.g., cell suspension analysis) and IMC (e.g., spatial proteomics of tissue sections). We highlight their impactful applications in biomedicine, including proteomics, immunology, oncology, and neuroscience, emphasizing their roles in disease diagnosis, targeted drug development, and single-cell analysis. Despite these advancements, challenges such as nanomaterial biocompatibility, clinical scalability, and artificial intelligence (AI)-driven design are discussed, providing a roadmap for future research in personalized medicine and theranostics.
- 1 December 2025
- Published by Tsinghua University Press in Nano Biomedicine and Engineering
- Vol. 17 (4) , 455-480
Open AccessMetal Isotope-Tagged Nanomaterials for Mass Cytometry and Imaging: Advances and Biomedical Applications
Mass cytometry (cytometry by time-of-flight (CyTOF)) and imaging mass cytometry (IMC) are transformative technologies that combine flow cytometry principles with time-of-flight mass spectrometry (TOF-MS). By employing metal isotope-tagged antibodies instead of fluorophores, these techniques overcome spectral overlap limitations and enable high-dimensional, compensation-free analysis of complex biological systems at single-cell resolution. The performance of CyTOF and IMC critically depends on advanced nanomaterials labeled with stable metal isotopes, which are essential for improving sensitivity and multiplexing capacity. This review systematically discusses the design principles, synthesis methods, and functionalization strategies of mass-tagged nanomaterials tailored for CyTOF (e.g., cell suspension analysis) and IMC (e.g., spatial proteomics of tissue sections). We highlight their impactful applications in biomedicine, including proteomics, immunology, oncology, and neuroscience, emphasizing their roles in disease diagnosis, targeted drug development, and single-cell analysis. Despite these advancements, challenges such as nanomaterial biocompatibility, clinical scalability, and artificial intelligence (AI)-driven design are discussed, providing a roadmap for future research in personalized medicine and theranostics.
- Open Access
- 6 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9718
Synovial CXCL3+FOSL2+ Macrophages Mediate Inflammation via FOSL2/AP-1 in Rheumatoid Arthritis: A Single-Cell Transcriptome Analysis
Macrophages play a central role in joint inflammation and bone destruction in rheumatoid arthritis (RA). While activator protein-1 (AP-1) transcription factors have been implicated in RA pathogenesis, the specific roles of individual AP-1 members in regulating synovial macrophages remain unclear. To address this, two public single-cell transcriptomic datasets were first analyzed to profile synovial macrophages, and then to identify AP-1 family members and associated pathways via differential expression and gene set enrichment analyses. JUND, FOSL2, and FOSB were found to be highly enriched in the RA synovium, and a distinct CXCL3+FOSL2+ macrophage subset was identified, characterized by pro-inflammatory, metabolic, and differentiation-related pathways. Intercellular communication analysis further revealed that this CXCL3+FOSL2+ macrophage subset interacted with ACKR1+ endothelial cells within the synovial microenvironment. Validation in a large-cohort bulk transcriptomic dataset, together with functional assays using in vitro FOSL2 knockdown in U937 cell lines, further confirmed FOSL2’s role in promoting macrophage-driven inflammation. Collectively, these findings indicate that CXCL3+FOSL2+ macrophages drive RA synovitis via the FOSL2/AP-1 axis, highlighting a potential therapeutic target.
- 6 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9718
Open AccessSynovial CXCL3+FOSL2+ Macrophages Mediate Inflammation via FOSL2/AP-1 in Rheumatoid Arthritis: A Single-Cell Transcriptome Analysis
Macrophages play a central role in joint inflammation and bone destruction in rheumatoid arthritis (RA). While activator protein-1 (AP-1) transcription factors have been implicated in RA pathogenesis, the specific roles of individual AP-1 members in regulating synovial macrophages remain unclear. To address this, two public single-cell transcriptomic datasets were first analyzed to profile synovial macrophages, and then to identify AP-1 family members and associated pathways via differential expression and gene set enrichment analyses. JUND, FOSL2, and FOSB were found to be highly enriched in the RA synovium, and a distinct CXCL3+FOSL2+ macrophage subset was identified, characterized by pro-inflammatory, metabolic, and differentiation-related pathways. Intercellular communication analysis further revealed that this CXCL3+FOSL2+ macrophage subset interacted with ACKR1+ endothelial cells within the synovial microenvironment. Validation in a large-cohort bulk transcriptomic dataset, together with functional assays using in vitro FOSL2 knockdown in U937 cell lines, further confirmed FOSL2’s role in promoting macrophage-driven inflammation. Collectively, these findings indicate that CXCL3+FOSL2+ macrophages drive RA synovitis via the FOSL2/AP-1 axis, highlighting a potential therapeutic target.
- Open Access
- 5 September 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1617451
Enhancing the treatment potential of IL-17 antagonism in lupus nephritis: finding the right partner
The treatment of lupus nephritis (LN) has been benefiting from biologics targeting immune cells and cytokines. IL-17 antagonists have been investigated for their potential in LN treatment, with mixed results from case reports and randomized controlled trials. Here we provide an overview of the contributions of various immune cells and kidney resident cells to LN pathogenesis and discuss relevant biologics for LN treatment. We then explore our current understanding of IL-17 and IL-17-producing cells in LN pathogenesis and examine the status of IL-17 antagonists in LN treatment. Given the limited success in clinical studies with IL-17 antagonism alone for LN, we discuss possible rational combination biologic therapies, with a focus on the potential combination with antagonism of IL-36, a cytokine family associated with SLE disease activity. Thus, emerging evidence suggests that dual biologic therapy could enhance disease control in LN.
- 5 September 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1617451
Open AccessEnhancing the treatment potential of IL-17 antagonism in lupus nephritis: finding the right partner
The treatment of lupus nephritis (LN) has been benefiting from biologics targeting immune cells and cytokines. IL-17 antagonists have been investigated for their potential in LN treatment, with mixed results from case reports and randomized controlled trials. Here we provide an overview of the contributions of various immune cells and kidney resident cells to LN pathogenesis and discuss relevant biologics for LN treatment. We then explore our current understanding of IL-17 and IL-17-producing cells in LN pathogenesis and examine the status of IL-17 antagonists in LN treatment. Given the limited success in clinical studies with IL-17 antagonism alone for LN, we discuss possible rational combination biologic therapies, with a focus on the potential combination with antagonism of IL-36, a cytokine family associated with SLE disease activity. Thus, emerging evidence suggests that dual biologic therapy could enhance disease control in LN.
- Open Access
- 10 July 2025
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 27 (1) , 1-10
nCD64 index as a new early predictive biomarker for macrophage activation syndrome in adult-onset still’s disease
Macrophage activation syndrome (MAS) represents a severe and potentially life-threatening complication of adult-onset Still’s disease (AOSD), necessitating the identification of sensitive and specific biomarkers for early diagnosis. Our study found significantly elevated CD64 mRNA expression in neutrophils of AOSD patients compared to healthy controls (p = 0.029). The neutrophil CD64 index (nCD64 index) positively correlated with key clinical manifestations, including splenomegaly, sore throat, pulmonary infiltrates, and pericarditis. Effective treatments led to a rapid and significant decrease in the nCD64 index (p < 0.001). Logistic regression showed that an elevated nCD64 index is a risk factor for MAS (OR = 1.073, p = 0.003). ROC curve analysis indicated that the nCD64 index reliably distinguished AOSD patients with MAS (AUC = 0.877; cutoff = 32.09; p < 0.001) and combined utilization of nCD64 index, ferritin, and sIL-2R demonstrated a strong predictive value. Correlations with hospitalization length (r = 0.382, p < 0.001) and maximum glucocorticoid dose (r = 0.326, p = 0.003) were also observed. Kaplan-Meier analysis revealed a significantly higher cumulative incidence of MAS in patients with an nCD64 index > 32.09 (p < 0.001). These findings suggest the nCD64 index is a promising biomarker for early identifying AOSD patients at risk of MAS, aiding in timely diagnosis and management.
- 10 July 2025
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 27 (1) , 1-10
Open AccessnCD64 index as a new early predictive biomarker for macrophage activation syndrome in adult-onset still’s disease
Macrophage activation syndrome (MAS) represents a severe and potentially life-threatening complication of adult-onset Still’s disease (AOSD), necessitating the identification of sensitive and specific biomarkers for early diagnosis. Our study found significantly elevated CD64 mRNA expression in neutrophils of AOSD patients compared to healthy controls (p = 0.029). The neutrophil CD64 index (nCD64 index) positively correlated with key clinical manifestations, including splenomegaly, sore throat, pulmonary infiltrates, and pericarditis. Effective treatments led to a rapid and significant decrease in the nCD64 index (p < 0.001). Logistic regression showed that an elevated nCD64 index is a risk factor for MAS (OR = 1.073, p = 0.003). ROC curve analysis indicated that the nCD64 index reliably distinguished AOSD patients with MAS (AUC = 0.877; cutoff = 32.09; p < 0.001) and combined utilization of nCD64 index, ferritin, and sIL-2R demonstrated a strong predictive value. Correlations with hospitalization length (r = 0.382, p < 0.001) and maximum glucocorticoid dose (r = 0.326, p = 0.003) were also observed. Kaplan-Meier analysis revealed a significantly higher cumulative incidence of MAS in patients with an nCD64 index > 32.09 (p < 0.001). These findings suggest the nCD64 index is a promising biomarker for early identifying AOSD patients at risk of MAS, aiding in timely diagnosis and management.
- Open Access
- 2 June 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1-17
IL-6R blockade combined with immunosuppressants alleviates adult-onset Still’s disease through immune remodeling: a mass cytometry study
Early administration of IL-6R blockade is effective in adult-onset Still’s disease (AOSD), but the underlying immune alterations during combined immunotherapy remain unclear. We employed high-dimensional single-cell mass cytometry and an unbiased bioinformatics pipeline to characterize the immune landscape in treatment-naïve AOSD patients, stable AOSD patients after 24 weeks of IL-6R blockade plus methotrexate and prednisone, and matched healthy controls. Cytokine profiling was conducted using a high-throughput cytometric bead array, and potential regulatory networks were identified using the PerformanceAnalytics package. Validation was performed via flow cytometry and mRNA sequencing. We identified 22 peripheral immune cell populations and characterized their composition and phenotypic markers. Treatment-naïve AOSD patients exhibited significant depletion of CD4+ T cells and B cells, along with excessive activation of CD8+ T cells and a previously unreported CD45+CD3−CD19−CD10−CD66a+ population, findings that were validated in an independent AOSD cohort. mRNA sequencing revealed the proinflammatory role of CD8+ T cells. Notably, these dysregulated immune profiles were markedly restored following immunotherapy. IL-18, IL-21, and IFN-γ demonstrated strong associations with adaptive immune cells and AOSD clinical indices. Combined IL-6R blockade effectively modulates immune dysregulation in refractory AOSD, reversing key pathological immune alterations and highlighting its therapeutic potential.
- 2 June 2025
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 23 (1) , 1-17
Open AccessIL-6R blockade combined with immunosuppressants alleviates adult-onset Still’s disease through immune remodeling: a mass cytometry study
Early administration of IL-6R blockade is effective in adult-onset Still’s disease (AOSD), but the underlying immune alterations during combined immunotherapy remain unclear. We employed high-dimensional single-cell mass cytometry and an unbiased bioinformatics pipeline to characterize the immune landscape in treatment-naïve AOSD patients, stable AOSD patients after 24 weeks of IL-6R blockade plus methotrexate and prednisone, and matched healthy controls. Cytokine profiling was conducted using a high-throughput cytometric bead array, and potential regulatory networks were identified using the PerformanceAnalytics package. Validation was performed via flow cytometry and mRNA sequencing. We identified 22 peripheral immune cell populations and characterized their composition and phenotypic markers. Treatment-naïve AOSD patients exhibited significant depletion of CD4+ T cells and B cells, along with excessive activation of CD8+ T cells and a previously unreported CD45+CD3−CD19−CD10−CD66a+ population, findings that were validated in an independent AOSD cohort. mRNA sequencing revealed the proinflammatory role of CD8+ T cells. Notably, these dysregulated immune profiles were markedly restored following immunotherapy. IL-18, IL-21, and IFN-γ demonstrated strong associations with adaptive immune cells and AOSD clinical indices. Combined IL-6R blockade effectively modulates immune dysregulation in refractory AOSD, reversing key pathological immune alterations and highlighting its therapeutic potential.